https://www.selleckchem.com/pr....oducts/liraglutide.h
The intertwining between cancer pathogenesis and aberrant expression of either oncogenes or tumor suppressor proteins ushered the cancer therapeutic approaches into a limitless road of modern therapies. For the nonce and among the plethora of promising anticancer agents, intense interest has focused on pioglitazone, a first in-class of Thiazolidinedione (TZD) drugs that is currently used to treat patients with diabetes. Intrigued by the overexpression of PPARγ in Acute Promylocytic Leukemia (APL), this study was designed to investig
Like
Comment
Share
